Table 1.
Patient characteristics
| Characteristics | Number of patients (%) |
|---|---|
| Total | 40 |
| median Age, y (range) | 39 (16–61) |
| ≥ 45 years | 29 (72.5%) |
| < 45 years | 11 (27.5%) |
| Gender | |
| Male | 28 (70.0%) |
| Female | 12 (30.0%) |
| Histopathological classification | |
| Diffuse large B cell lymphoma | 40 (100%) |
| Tumor bulk | |
| ≥ 10 cm | 7 (17.5%) |
| Number of prior chemotherapy regimens | |
| 2 | 6 (15.0%) |
| 3 | 12 (30.3%) |
| 4 or more | 22 (55.0%) |
| Number of prior chemotherapy cycles | |
| 6 | 3 (7.5%) |
| 8 | 5 (12.5%) |
| 9 or more | 32 (80.0%) |
| Previous radiation therapy | |
| Yes | 4 (10.0%) |
| No | 36 (90.0%) |
| B symptoms | 25 (62.5%) |
| Extranodal disease | 37 (92.5%) |
| Conditioning regiments | |
| BEAM | 15 (37.5%) |
| CBV | 21 (52.5%) |
| LACE | 4 (10.0%) |
| Refractory status | |
| Primary refractory | 26 (65.0%) |
| Relapse refractory | 14 (35.0%) |
| ECOG | |
| 0–2 | 17 (42.5%) |
| 3–4 | 23 (57.5%) |
| Previous rituximab therapy | |
| Yes | 37 (92.5%) |
| No | 3 (7.5%) |